Skip to main content

Advertisement

SpringerLink
Log in

Calcineurin inhibitor-free GVHD prophylaxis with sirolimus and mycophenolate mofetil combination

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Deeg HJ, Storb R, Thomas ED, Flournoy N, Kennedy MS, Banaji M, Appelbaum FR, Bensinger WI, Buckner CD, Clift RA (1985) Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 65:1325–1334

    CAS  PubMed  Google Scholar 

  2. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O’Donnell MR, Parker PM (1993) Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225–1230

    Article  CAS  PubMed  Google Scholar 

  3. Field EH, Matesic D, Rigby S, Fehr T, Rouse T, Gao Q (2001) CD4+CD25+ regulatory cells in acquired MHC tolerance. Immunol Rev 182:99–112

    Article  CAS  PubMed  Google Scholar 

  4. Kingsley CI, Karim M, Bushell AR, Wood KJ (2002) CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol (Baltimore, Md : 1950) 168:1080–1086

  5. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ, Ritz J (2005) Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 106:2903–2911

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, Keyvanfar K, Montero A, Hensel N, Kurlander R, Barrett AJ (2006) High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108:1291–1297

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9:1144–1150

    Article  CAS  PubMed  Google Scholar 

  8. Coenen JJA, Koenen HJPM, van Rijssen E, Kasran A, Boon L, Hilbrands LB, Joosten I (2007) Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant 39:537–545

    Article  CAS  PubMed  Google Scholar 

  9. Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV, Koreth J, Alyea EP, Soiffer RJ, Cutler CS, Antin JH, Baden LR (2007) Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 110:490–500

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R (2012) Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant 47:581–588

    Article  CAS  PubMed  Google Scholar 

  11. Schleuning M, Judith D, Jedlickova Z, Stübig T, Heshmat M, Baurmann H, Schwerdtfeger R (2009) Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant 43:717–723

    Article  CAS  PubMed  Google Scholar 

  12. Bejanyan N, Rogosheske J, Defor TE, Holtan S, Jacobson P, MacMillan ML, Verneris MR, Arora M, Lazaryan A, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG (2016) Sirolimus/mycophenolate mofetil (MMF): effective calcineurin inhibitor-free gvhd prophylaxis for reduced Intensity conditioning (RIC) umbilical cord blood (UCB) transplantation. Biol Blood Marrow Transplant Elsevier 22:S305

    Article  Google Scholar 

  13. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H-J (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol Off J Am Soc Clin Oncol 23:5675–5687

    Article  Google Scholar 

  14. Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, Antin JH (2007) Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood Am Soc Hematol 109deeg:3108–3114

    Google Scholar 

  15. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ (2003) Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102:1601–1605

    Article  CAS  PubMed  Google Scholar 

  16. Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R (2008) Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 112:4425–4431

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Platzbecker U, von Bonin M, Goekkurt E, Radke J, Binder M, Kiani A, Stoehlmacher J, Schetelig J, Thiede C, Ehninger G, Bornhäuser M (2009) Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 15:101–108

    Article  CAS  Google Scholar 

  18. Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, de Oteiza JP, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F (2016) Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 374:43–53

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology/Oncology, Bone Marrow Transplant, University of Massachusetts Medical Center and Medical School, 55 Lake Avenue N, Worcester, MA, 01655, USA

    Neeraj Saini & Jan Cerny

  2. Bone Marrow Transplant, Banner MD Anderson Cancer Center, Gilbert, AZ, USA

    Rajneesh Nath

Authors
  1. Neeraj Saini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rajneesh Nath
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan Cerny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Cerny.

Ethics declarations

All authors acknowledge no financial interests or motives in contribution of the manuscript.

Each author has participated sufficiently in the work to take public responsibility for the content.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).

Informed consent was obtained from all patients for being included in the study.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saini, N., Nath, R. & Cerny, J. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus and mycophenolate mofetil combination. Ann Hematol 96, 1563–1568 (2017). https://doi.org/10.1007/s00277-017-3062-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3062-2

Search

Navigation